Download PDF
1 / Pages

Other users also viewed these articles

Prevalence and risk factors of significant fibrosis in chronic hepatitis B patients with concurrent metabolic dysfunction-associated steatotic liver disease Shan Hong; Yiwei Hao; Lei Sun; Ping Li; Junru Yang; Fuyang Zhang; Lingling He; Jing Zhang; Hongshan Wei;
10.1016/j.aohep.2024.101589
NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: A multi-center, retrospective study Renling Yao; Sufang Lu; Ruifei Xue; Jian Wang; Yuanwang Qiu; Yuxin Chen; Jiacheng Liu; Li Zhu; Jie Zhan; Suling Jiang; Shengxia Yin; Xin Tong; Weimao Ding; Jie Li; Chuanwu Zhu; Rui Huang; Chao Wu;
Ann Hepatol. 2024;29:
Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study Samantha Thifani Alrutz Barcelos; Amanda Souza Silva-Sperb; Helena Abadie Moraes; Larisse Longo; Bruna Concheski de Moura; Matheus Truccolo Michalczuk; Carolina Uribe-Cruz; Carlos Thadeu Schmidt Cerski; Themis Reverbel da Silveira; Valesca Dall'Alba; Mário Reis Álvares-da-Silva;
Ann Hepatol. 2023;28: